• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CRISPR Therapeutics AG filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:05:15 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRSP alert in real time by email
    8-K
    false000167441600-000000000016744162025-05-062025-05-06

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2025

     

     

    CRISPR THERAPEUTICS AG

    (Exact name of registrant as specified in its charter)

     

     

    Switzerland

    001-37923

    Not Applicable

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

     

     

    Baarerstrasse 14

     

    6300 Zug, Switzerland

     

    Not Applicable

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: 41 (0)41 561 32 77

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

     

    Name of each exchange on which registered

    Common Shares, nominal value CHF 0.03

     

    CRSP

     

    The NASDAQ Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

    ☐

     

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits:

    The following exhibits shall be deemed to be furnished, and not filed:

     

    Exhibit

    No.

     

    Description

     

     

    99.1

    Press Release by CRISPR Therapeutics AG, dated May 6, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    CRISPR Therapeutics AG

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Samarth Kulkarni

     

     

     

    Samarth Kulkarni, Ph.D.

    Chief Executive Officer

     

     

     


    Get the next $CRSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRSP

    DatePrice TargetRatingAnalyst
    2/14/2025$60.00 → $99.00In-line → Outperform
    Evercore ISI
    2/12/2025$35.00Sell → Hold
    TD Cowen
    2/3/2025$65.00Buy
    H.C. Wainwright
    8/6/2024$88.00 → $84.00Buy
    Needham
    8/2/2024$90.00Buy
    Rodman & Renshaw
    6/28/2024Neutral
    Guggenheim
    2/15/2024Peer Perform
    Wolfe Research
    12/11/2023$30.00Market Perform → Underperform
    TD Cowen
    More analyst ratings

    $CRSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

      -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain momentum; more than 65 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 90 patients have had cells collected across all regions; new patient initiations expected to grow significantly in 2025- -Clinical trial ongoing for CTX320™, targeting the LPA gene; top-line data update on track for the second quarter of 2025- -Clinic

      5/6/25 4:01:00 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics Since its ince

      4/3/25 8:00:00 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics Announces Transition of Chief Operating Officer

      ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. "Julie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model," said Samarth Kulkarni, Ph.D., Chairman and Ch

      3/26/25 4:01:00 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Greene John bought $313,948 worth of shares (7,000 units at $44.85) (SEC Form 4)

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      2/28/25 5:35:05 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CRISPR Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously

      2/14/25 8:06:15 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics upgraded by TD Cowen with a new price target

      TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00

      2/12/25 7:01:19 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on CRISPR Therapeutics with a new price target

      H.C. Wainwright initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $65.00

      2/3/25 7:05:27 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

      SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

      12/10/24 1:34:45 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

      SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

      4/10/24 11:58:51 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

      SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

      2/12/24 6:22:35 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    SEC Filings

    See more
    • SEC Form 10-Q filed by CRISPR Therapeutics AG

      10-Q - CRISPR Therapeutics AG (0001674416) (Filer)

      5/6/25 4:10:28 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics AG filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CRISPR Therapeutics AG (0001674416) (Filer)

      5/6/25 4:05:15 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by CRISPR Therapeutics AG

      DEFA14A - CRISPR Therapeutics AG (0001674416) (Filer)

      4/16/25 4:10:13 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Leadership Updates

    Live Leadership Updates

    See more

    $CRSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CRISPR Therapeutics Proposes New Appointment to the Board of Directors

      ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip

      1/7/25 8:00:00 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

      -Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al

      5/23/24 8:00:00 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics Announces Transition of Chief Financial Officer

      ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec

      3/13/23 4:15:00 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Bruno Julianne converted options into 3,750 shares and sold $70,668 worth of shares (1,714 units at $41.23), increasing direct ownership by 24% to 10,544 units (SEC Form 4)

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      3/24/25 5:35:07 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Kulkarni Samarth sold $413,578 worth of shares (10,031 units at $41.23) and converted options into 19,688 shares, increasing direct ownership by 5% to 195,085 units (SEC Form 4)

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      3/24/25 5:35:09 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel and Secretary Kasinger James R. converted options into 6,250 shares and sold $131,318 worth of shares (3,185 units at $41.23), increasing direct ownership by 4% to 81,729 units (SEC Form 4)

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      3/24/25 5:35:04 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Financials

    Live finance-specific insights

    See more
    • CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

      -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20

      10/12/21 4:01:00 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

      -Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web

      10/5/21 4:05:00 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care